EXCALIBER-RRMM Halves Progression Risk; Zenbexus Gets FDA Nod
BMY sits 44% above its 52-week low of $42.52.
Summary
The weekly recap adds granular Phase 3 data: EXCALIBER-RRMM showed median PFS of 42 months vs 20 months for DVd (HR 0.49, p<0.000001, n=800), a striking efficacy signal in relapsed/refractory multiple myeloma. Zenbexus (iberdomide) already received FDA accelerated approval in August, but the recap confirms it as the first CELMoD protein degrader cleared for combination therapy. New ALOFT-IPF details show Admilparant 60 mg significantly improved FVC at Week 52, while the 120 mg dose missed significance—a mixed but still positive read for the IPF program. Separately, AL101 patent rights were assigned to Immunome on Oct 2, removing milestone and royalty obligations. These data points reinforce BMY's late-stage pipeline momentum, though the stock dipped ~1.4% on the week's results, suggesting some profit-taking after prior gains.
At the time of this announcement, BMY was trading at $61.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $120.8B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.